UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

doi:10.5489/cuaj.8054

. 2022 Aug;16(8):E416-E431.

doi: 10.5489/cuaj.8054.

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Affiliations

¹ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
² Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
³ Department of Surgery, Division of Urology, Memorial University, St. John's, NL, Canada.
⁴ Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁵ Department of Urology, Queen's University, Kingston, ON, Canada.
⁶ Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
⁷ CHU de Quebec, Université Laval, Quebec City, QC, Canada.
⁸ Department of Surgery (Urology) and Oncology, McMaster University, Hamilton, ON, Canada.
⁹ McGill University Health Centre, Montreal, QC, Canada.
¹⁰ Department of Urology, Dalhousie, University, Halifax, NS, Canada.

PMID: 35905482
PMCID: PMC9343157
DOI: 10.5489/cuaj.8054

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Andrea Kokorovic et al. Can Urol Assoc J. 2022 Aug.

. 2022 Aug;16(8):E416-E431.

doi: 10.5489/cuaj.8054.

Authors

Affiliations

¹ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
² Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
³ Department of Surgery, Division of Urology, Memorial University, St. John's, NL, Canada.
⁴ Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁵ Department of Urology, Queen's University, Kingston, ON, Canada.
⁶ Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
⁷ CHU de Quebec, Université Laval, Quebec City, QC, Canada.
⁸ Department of Surgery (Urology) and Oncology, McMaster University, Hamilton, ON, Canada.
⁹ McGill University Health Centre, Montreal, QC, Canada.
¹⁰ Department of Urology, Dalhousie, University, Halifax, NS, Canada.

PMID: 35905482
PMCID: PMC9343157
DOI: 10.5489/cuaj.8054

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. So has been an advisory board member for AbbVie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Izard has received a grant(s) or honoraria from AbbVie, Astellas, Bayer, Ferring, Janssen, and Sanofi; and has participated in clinical trials supported by AbbVie, Astellas, AstraZeneca, Bayer, Janssen, and Merck. Dr. Saad has been an advisory board member for and has received payment/honoraria from AbbVie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Aprikian has been an advisory board member for AbbVie, Astellas, and Bayer; and has received grants from AbbVie, Astellas Bayer, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. The remaining authors report no competing personal or financial interests related to this work. The remaining authors report no competing personal or financial interests related to this work.

Figures

**Fig. 1**
Multidisciplinary approach to managing patients on androgen deprivation therapy (ADT). BMD: bone mineral density; BMI: body mass index; CUA: Canadian Urological Association; DXA: dual energy x-ray absorptiometry; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MACE: major adverse cardiac events; PCP: primary care physician; VTE: venous thromboembolism.

See this image and copyright information in PMC

Cited by

Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease.
Rogé M, Guimas V, Rio E, Vaugier L, Perennec T, Alexandre J, Supiot S, Martin Mervoyer E. Rogé M, et al. Cancers (Basel). 2023 Aug 17;15(16):4157. doi: 10.3390/cancers15164157. Cancers (Basel). 2023. PMID: 37627185 Free PMC article.
Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care.
Shawky NM, Reckelhoff JF, Alexander BT, Yanes Cardozo LL. Shawky NM, et al. Hypertension. 2023 Sep;80(9):1810-1820. doi: 10.1161/HYPERTENSIONAHA.123.19501. Epub 2023 Jul 18. Hypertension. 2023. PMID: 37462057 Free PMC article. Review.
Management of vasomotor symptoms in cancer patients.
Zhu L, Hshieh TT, Iyer TK, Morgans AK, Hamnvik OR. Zhu L, et al. Oncologist. 2025 Feb 6;30(2):oyaf002. doi: 10.1093/oncolo/oyaf002. Oncologist. 2025. PMID: 40037618 Free PMC article. Review.
Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians.
Nguyen DD, Mousa A, Klotz L, Niazi T, Pouliot F, Kokorovic A, Lavallée LT, Huynh M, Lapointe N, Di Risio M, Wallis CJD. Nguyen DD, et al. Can Urol Assoc J. 2024 Jun;18(6):212-215. doi: 10.5489/cuaj.8687. Can Urol Assoc J. 2024. PMID: 38587979 Free PMC article. No abstract available.
Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.
Chang WT, Hong JH, Chen DY, Huang CY, Chen YC, Cha TL, Wu YW, Lin TP, Cheng KH, Chiang PJ, Hung CL, Wang SS, Wang WH, Shao IH, Liao JN, Hung SC, Lin HJ, Huang SP, Liu PY, Huang KH, Wang TD, Lin JT, Li YH, Wu HC, Pang JS, Chen WJ. Chang WT, et al. Acta Cardiol Sin. 2025 May;41(3):288-310. doi: 10.6515/ACS.202505_41(3).20250224A. Acta Cardiol Sin. 2025. PMID: 40416564 Free PMC article.

References

1. 2020, Canadian Cancer Statistics 2020. Canadian Cancer Society;
1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society; 2018.
1. Center for Evidence-Based Medicine (CEBM) 2018. [Accessed Feb 13, 2021]. Available at: https://www.cebm.net.
1. The Grading of Recommendations: Assessment, Development, and Evaluation (GRADE) working group. 2018. [Accessed Feb 12, 2021]. Available at: http://www.gradeworkinggroup.org.
1. Pagliarulo V. Androgen Deprivation Therapy for Prostate Cancer. In: Schatten H, editor. Molecular & Diagnostic Imaging in Prostate Cancer: Clinical Applications and Treatment Strategies. Cham: Springer International Publishing; 2018. pp. 1–30. - DOI

LinkOut - more resources

Full Text Sources

[1] 2020, Canadian Cancer Statistics 2020. Canadian Cancer Society;

[2] 2020, Canadian Cancer Statistics 2020. Canadian Cancer Society;

[3] Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society; 2018.

[4] Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society; 2018.

[5] Center for Evidence-Based Medicine (CEBM) 2018. [Accessed Feb 13, 2021]. Available at: https://www.cebm.net.

[6] Center for Evidence-Based Medicine (CEBM) 2018. [Accessed Feb 13, 2021]. Available at: https://www.cebm.net.

[7] The Grading of Recommendations: Assessment, Development, and Evaluation (GRADE) working group. 2018. [Accessed Feb 12, 2021]. Available at: http://www.gradeworkinggroup.org.

[8] The Grading of Recommendations: Assessment, Development, and Evaluation (GRADE) working group. 2018. [Accessed Feb 12, 2021]. Available at: http://www.gradeworkinggroup.org.

[9] Pagliarulo V. Androgen Deprivation Therapy for Prostate Cancer. In: Schatten H, editor. Molecular & Diagnostic Imaging in Prostate Cancer: Clinical Applications and Treatment Strategies. Cham: Springer International Publishing; 2018. pp. 1–30. - DOI

[10] Pagliarulo V. Androgen Deprivation Therapy for Prostate Cancer. In: Schatten H, editor. Molecular & Diagnostic Imaging in Prostate Cancer: Clinical Applications and Treatment Strategies. Cham: Springer International Publishing; 2018. pp. 1–30. - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Affiliations

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources